



cefe
PATENT
675301-2018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Gholam Peyman
Patent No. : 7,087,237
Issue Date : August 8, 2006
Application No. : 10/667,161
Filing Date : September 19, 2003
For : Ocular Solutions

745 Fifth Avenue, New York, NY 10151

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Angela M. Collison, Reg. No. 51,107

Name of Applicant, Assignee or Registered Representative

Angela M. Collison

Signature

August 23, 2006

Date of Signature

Certificate
AUG 31 2006
of Correction

REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

It is requested that a Certificate of Correction be issued in the above-entitled patent in accordance with the accompanying form PTO 1050. Please make the following changes:

08/30/2006 SFELEKE2 00000032 7087237

01 FC:1811

100.00 GP

AUG 31 2006

IN THE CLAIMS:

Column 9, claim 2 line 28

The method of claim 1 wherein the macrolide antibiotic or mycophenolic acid --further-- provides at least one selected from the group consisting of an anti-inflammatory effect, an anti-cell proliferation effect, an anti-cell migration effect, an anti-angiogenesis effect, an antimicrobial effect, and an antifungal effect.

Column 10, claim 14 line 12

The article of claim 12 wherein the macrolide antibiotic is at least one selected from the --group consisting-- of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.

AUG 31 2006

REMARKS

Since one of the errors to be corrected is the Applicant's error, check No. 41225 of \$100 is enclosed for payment of the fee. The requested changes do not constitute new matter and this application does not require re-examination. A completed Form PTO 1050 is enclosed. The Commissioner is authorized to charge any additional fees or credit any overpayments to Deposit Account No. 50-0320.

Respectfully submitted,
FROMMER LAWRENCE & HAUG LLP
Attorney for Applicant

By: Thomas J. Kowalski by Angela M. Collison
Thomas J. Kowalski
Reg. No. 32,147

Anne-Marie C. Yvon
Reg. No. 52,390

Angela M. Collison
Reg. No. 51,107

AUG 31 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO : 7,087,237
DATED : August 8, 2006
INVENTOR(S) : Gholam Peyman

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 9, claim 2 line 28

The method of claim 1 wherein the macrolide antibiotic or mycophenolic acid --further-- provides at least one selected from the group consisting of an anti-inflammatory effect, an anti-cell proliferation effect, an anti-cell migration effect, an anti-angiogenesis effect, an antimicrobial effect, and an antifungal effect.

Column 10, claim 14 line 12

The article of claim 12 wherein the macrolide antibiotic is at least one selected from the --group consisting-- of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.

MAILING ADDRESS OF SENDER:
Thomas J. Kowalski, Esq.
Frommer Lawrence & Haug LLP
745 Fifth Avenue
New York, New York 10151

PATENT NO. 7,087,237
No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.1 and 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing, and submitting the complete provisional application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

00393536

AUG 21 2006